Pharmaceutical practice of acute liver injury in a patient with nintedanib-induced lung cancer complicated with interstitial pneumonia

Published on Nov. 07, 2024Total Views: 736 times Total Downloads: 166 times Download Mobile

Author:  ZHANG Juan ^1, ² SHEN Lihuan ^2, ³ LIU Jiyong ^1, ²  WANG Chunmin ^1, ²

Affiliation: 1. Department of Pharmacy, Fudan University Shanghai Cancer Center, Shanghai 200032, China 2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China 3. Department of Critical Care, Fudan University Shanghai Cancer Center, Shanghai 200032, China

Keywords: Nintedanib Lung cancer with interstitial pneumonia Acute liver injury Pharmaceutical practice

DOI: 10.12173/j.issn.1005-0698.202407015

Reference: ZHANG Juan, SHEN Lihuan, LIU Jiyong, WANG Chunmin.Pharmaceutical practice of acute liver injury in a patient with nintedanib-induced lung cancer complicated with interstitial pneumonia[J].Yaowu Liuxingbingxue Zazhi,2024, 33(10):1178-1182.DOI: 10.12173/j.issn.1005-0698.202407015.[Article in Chinese]  Copied

Abstract
Full-text
References

Abstract

This article reports the pharmacotherapy process of a clinical pharmacist participating in the treatment of acute liver injury caused by nintedanib in a patient with lung cancer complicated with interstitial pneumonia. Clinical pharmacist analyzed the rapid increase of liver enzymes in patients by excluding their past drug use history, stopping suspicious drugs and searching domestic and foreign literature, and determined that the association with nidanib was very likely according to RUCAM scale. The clinical pharmacies suggesteded stopping nintedanib and taking liver protection treatment actively. The clinician adopted the suggestion, and finally the patient’s liver function improved after 20 days of treatment. Clinical pharmacists demonstrate their value by analyzing the causes and characteristics of liver injury in patients, assisting physicians in the timely identification and management of adverse reactions, and participating in clinical practice. This article can provide a reference for the diagnosis and treatment of similar cases of acute liver injury.

Full-text

Please download the PDF version to read the full text: download

References

1.Ichihara E, Miyahara N, Maeda Y, et al. Managing lung cancer with comorbid interstitial pneumonia[J]. Intern Med, 2020, 59(2): 163-167. DOI: 10.2169/internalmedicine. 3481-19.

2.Ogura T, Takigawa N, Tomii K, et al. Summary of Japanese respiratory society statement for the treatment of lung cancer with comorbid interstitial pneumonia[J]. Respir Investing, 2019, 57(6): 512-533. DOI: 10.1016/j.resinv.2019.06.001.

3.Lamb YN. Nintedanib: a review in fibrotic interstitial lung diseases[J]. Drugs, 2021, 81(5): 575-586. DOI: 10.1007/s40265-021-01487-0.

4.中国医药生物技术协会药物性肝损伤防治技术专业委员会, 中华医学会肝病学分会药物性肝病学组. 中国药物性肝损伤诊治指南(2023年版)[J]. 胃肠病学, 2023, 28(7): 397-431. [Technology Committee on DILI Prevention and Management, Chinese Medical Biotechnology Association; Study Group of Drug; Induced Liver Disease, Chinese Medical Association for the Study of Liver Diseases. Chinese guideline for diagnosis and management of drug-induced liver injury (2023 version) [J]. Chinese Journal of Gastroenterology, 2023, 28(7): 397-431.] DOI: 10.3760/cma.j.cn501113-20230419-00176.

5.Emanuel R, Michele F, Milo G, et al. Liver injury with nintedanib: a pharmacovigilance-pharmacokinetic appraisal[J]. Pharmaceuticals (Basel), 2022, 15(5): 645. DOI: 10.3390/ph15050645.

6.Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis[J]. N Engl J Med, 2014, 370(22): 2071-2082. DOI: 10.1056/NEJMoa1402584.

7.Olin JL, Woods JA, Garner SJ. Delayed presentation of hepatocellular liver injury after nintedanib administration[J]. Am J Ther, 2017, 24(1): e107-e108. DOI: 10.1097/MJT.0000000000000464.

8.Jena A, Aggarwal T, Mitra S, et al. Nintedanib-induced liver injury: not every liver injury is virus or vaccine-inducedin the era of COVID-19[J]. Liver Int, 2022, 42(5): 1210-1211. DOI: 10.1111/liv.15206.

9.Liver Tox: Clinical and Research Information on drug-Induced liver injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–Nintedanib[EB/OL]. (2023-12-12) [2024-03-01]. https://www.ncbi.nlm.nih.gov/boks/NBK548135/.

10.陈喆, 秦艳, 叶岩荣. 尼达尼布致不良反应文献分析[J]. 中国新药杂志, 2024, 33(3): 307-312. [Chen Z, Qin Y, Ye YR. Literature analysis of adverse drug reactions induced by nintedanib[J]. Chinese Journal of New Drugs, 2024, 33(3): 307-312.] DOI: 10.3969/j.issn.1003-3734.2024.03.015.

11.张显彬, 于眉, 李玲, 等. 药物性肝损伤研究进展 [J]. 中国现代医院杂志, 2024, 26(1): 107-110. DOI: 10.3969/j.issn.1672-9463.2024.01.024.

12.王晓艳, 李伟霞, 张辉, 等. 复方甘草酸苷防治药物性肝损伤有效性与安全性的Meta分析[J]. 实用中医内科杂志, 2021, 35(1): 22-27. [Wang XY, Li WX, Zhang H, et al. Meta-analysis on effectiveness and safety of compound glycyrrhizin for drug-induced liver injury[J]. Journal of Practical Traditional Chinese Internal Medicine, 2021, 35(1): 22-27.] DOI: 10.13729/j.issn.1671-7813.Z20200473.

13.朱月萍, 钱峰, 朱伟, 等. 复方甘草酸苷与还原性谷胱甘肽联用对药物性肝损伤患者肝功能指标改善作用的疗效评价[J]. 抗感染药学, 2017, 14(5): 995-996. [Zhu YP, Qian F, Zhu W, et al. Clinical efficacy of improving liver function using compound glycyrrhizin combined with glutathione in patients with drugs liver damages[J]. Anti-Infection Pharmacy, 2017, 14(5): 995-996.] DOI: 10.13493/j.issn.1672-7878.2017.05-034.